Gracell Biotechnologies Inc. is a clinical-stage biotechnology company that develops and commercializes cellular immunotherapies to treat cancer. The company's focus is on developing next-generation, personalized cellular immunotherapies for the treatment of hematologic malignancies and solid tumors. Gracell's products are based on its proprietary FasTCAR and TruUCAR technologies, which allow for the development of off-the-shelf and customized chimeric antigen receptor T-cell therapies.
The company was founded in 2017 and is headquartered in Suzhou, China, with additional offices in the United States and Australia. Gracell has a strong research and development program, with a team of over 200 employees and a dedicated manufacturing facility in China.
Gracell went public on the Nasdaq Global Select Market in February 2021, raising approximately $100 million in its initial public offering. The company's shares trade under the ticker symbol GRCL. The proceeds from the IPO will be used to support the company's ongoing clinical development programs, as well as to expand its manufacturing capabilities and strengthen its global commercialization efforts.
Gracell has several product candidates in various stages of clinical development, including its lead candidate, GC012F, a FasTCAR-enabled CAR-T therapy for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia. The company is also developing TruUCAR-enabled CAR-T therapies for multiple indications, including solid tumors.
Gracell's mission is to develop innovative cellular immunotherapies that have the potential to transform the treatment of cancer. The company is committed to advancing its technology platform and pipeline of product candidates, with the goal of delivering safe and effective therapies to patients in need.